Abstract
The skin is the ultimate example of the function of innate immunity, it alerts the host of danger by many systems including sensing pathogen-associated molecule patterns (PAMPs) through Toll-like receptors and other pattern recognition receptors (PRRs), yet normally provides defense without inflammation. The skin responds rapidly to invading microbes by producing antimicrobial peptides or other antimicrobial intermediates before cytokine release results in inflammation. To achieve maximal immune responses for clearing invading microbes, the activation of select PRRs in skin then initiates and shapes adaptive immune responses through the activation of dendritic cells and recruitment of T cell subsets. Importantly, cross-talk between TLRs can influence this system in several ways including augmenting or suppressing the immune response. As a consequence of their pivotal role, TLR responses need to be tightly controlled by associated negative regulators or negative feedback loops to prevent detrimental effects from TLRs overactivation. This review focuses on describing the involvement of TLRs in the development of skin infections and inflammatory diseases, and highlights the potential application of TLR agonists or antagonists in these skin diseases.
Keywords: Toll-like receptors, TLR signaling, inflammatory cytokines, antimicrobial peptides, cross talk, negative regulators, skin infections, inflammatory diseases
Infectious Disorders - Drug Targets
Title: Toll-Like Receptors in Skin Infections and Inflammatory Diseases
Volume: 8 Issue: 3
Author(s): Yuping Lai and Richard L. Gallo
Affiliation:
Keywords: Toll-like receptors, TLR signaling, inflammatory cytokines, antimicrobial peptides, cross talk, negative regulators, skin infections, inflammatory diseases
Abstract: The skin is the ultimate example of the function of innate immunity, it alerts the host of danger by many systems including sensing pathogen-associated molecule patterns (PAMPs) through Toll-like receptors and other pattern recognition receptors (PRRs), yet normally provides defense without inflammation. The skin responds rapidly to invading microbes by producing antimicrobial peptides or other antimicrobial intermediates before cytokine release results in inflammation. To achieve maximal immune responses for clearing invading microbes, the activation of select PRRs in skin then initiates and shapes adaptive immune responses through the activation of dendritic cells and recruitment of T cell subsets. Importantly, cross-talk between TLRs can influence this system in several ways including augmenting or suppressing the immune response. As a consequence of their pivotal role, TLR responses need to be tightly controlled by associated negative regulators or negative feedback loops to prevent detrimental effects from TLRs overactivation. This review focuses on describing the involvement of TLRs in the development of skin infections and inflammatory diseases, and highlights the potential application of TLR agonists or antagonists in these skin diseases.
Export Options
About this article
Cite this article as:
Lai Yuping and Gallo L. Richard, Toll-Like Receptors in Skin Infections and Inflammatory Diseases, Infectious Disorders - Drug Targets 2008; 8 (3) . https://dx.doi.org/10.2174/1871526510808030144
DOI https://dx.doi.org/10.2174/1871526510808030144 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inpatient Care of the HIV Infected Patient in the Highly Active Antiretroviral Therapy (HAART) Era
Current HIV Research Ethnic and Geographical Differences in Ischaemic Stroke Among Young Adults
Current Vascular Pharmacology Is There an Association between Periodontitis and Hypertension?
Current Cardiology Reviews Drug Delivery Systems Based on Titania Nanotubes and Active Agents for Enhanced Osseointegration of Bone Implants
Current Medicinal Chemistry Mass Spectrometry-Based Approaches for the Detection of Proteins of Staphylococcus Species
Infectious Disorders - Drug Targets Inhibition of Quorum Sensing in Staphylococcus spp.
Current Pharmaceutical Design Assay of Daptomycin Injection: Development and Validation of an Environment-friendly CZE Method
Current Pharmaceutical Analysis The Oral Cavity, Biofilms and Ventilator-Associated Pneumonia
Current Respiratory Medicine Reviews Adenovirus Mediated Herpes Simplex Virus-Thymidine Kinase/Ganciclovir Gene Therapy for Resectable Malignant Glioma
Current Gene Therapy Management of Asymptomatic Severe Aortic Stenosis
Current Cardiology Reviews Novel Approaches to Control Biofilm Infections
Current Medicinal Chemistry Acute Cardioembolic Cerebral Infarction: Answers to Clinical Questions
Current Cardiology Reviews Use of Diffusion- and Perfusion-Weighted Magnetic Resonance Imaging in Drug Development for Ischemic Stroke
Current Drug Targets - CNS & Neurological Disorders Daptomycin: A Review of Properties, Clinical Use, Drug Delivery and Resistance
Mini-Reviews in Medicinal Chemistry Nucleotide Second Messenger Signaling as a Target for the Control of Bacterial Biofilm Formation
Current Topics in Medicinal Chemistry Role of Old Antibiotics in Multidrug Resistant Bacterial Infections
Current Drug Targets Cardioembolic Stroke: Clinical Features, Specific Cardiac Disorders and Prognosis
Current Cardiology Reviews A Rare Case of Tricuspid Valve Endocarditis Caused by Enterococcus Gallinarum in a Patient with Recurrent Urinary Tract Infection
Cardiovascular & Hematological Disorders-Drug Targets The Family of Serratia Type Pore Forming Toxins
Current Protein & Peptide Science Editorial [Hot topic:Thromboembolism in Patients with Malignancy (Guest Editor: Ioannis Starakis)]
Cardiovascular & Hematological Disorders-Drug Targets